nach oben

The journal of nutrition, health & aging

Erschienen in:

10.10.2015

Effects of acetylcholinesterase inhibitors on nutritional status in elderly patients with dementia: A 6-month follow-up study

verfasst von: P. Soysal, Ahmet Turan Isik

Erschienen in: The journal of nutrition, health & aging | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Nutritional status is one of the factors that affects disease progression, morbidity and mortality in elderly patients with dementia. The present study aimed to evaluate the effect of acetylcholinesterase inhibitor (AchEI) therapy on nutritional status and food intake in the elderly.

Design, setting and participants

Newly diagnosed patients with dementia, who underwent comprehensive geriatric assessment (CGA) and were followed at regular intervals, were retrospectively evaluated. A total of 116 patients, who began to receive AchEI therapy and completed 6-month follow-up period under this treatment, were enrolled in the study.

Measurements

Socio-demographic characteristics and data on comorbidity, polypharmacy, cognitive function, depression, activities of daily living and nutritional status (weight, Body Mass Index (BMI), Mini Nutritional Assessment (MNA)-Short Form) were recorded.

Results

The mean age of the patients was 78.0±8.9 years. There was no significant difference between baseline and 6-month BMI, weight and MNA scores of dementia patients who received AchEI therapy (p>0.05). With regard to the relation between changes in BMI, weight and MNA on the 6th month versus baseline, and donepezil, rivastigmine and galantamine therapies, no difference was determined (p>0.05). However, no worsening in food intake was observed (kappa: 0.377). When the effects of each AchEI on food intake were compared, food intake in rivastigmine treated patients was not decreased as much as it was in galantamine or donepezil treated patients (p<0.05).

Conclusion

AchEI therapy has no unfavorable effect on nutritional status or weight in elderly patients with different types of dementia, but it seems that food intake is better in those treated by rivastigmine patch.

Orsitto G. Different components of nutritional status in older inpatients with cognitive impairment. J Nutr Health Aging. 2012;16(5):468–71.CrossRefPubMed

Volicer L, Seltzer B, Rheaume Y, Karner J, Glennon M, Riley ME, Crino P. Eating difficulties in patients with probable dementia of the Alzheimer type. J Geriatr Psychiatry Neurol. 1998;2(4):188–95CrossRef

Sergi G, De Rui M, Coin A, Inelmen EM, Manzato E. Weight loss and Alzheimer’s disease: temporal and aetiologic connections. Proc Nutr Soc. 2013;72(1):160–5.CrossRefPubMed

Uwano C, Suzuki M, Aikawa T et al. Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer’s disease. J Am Geriatr Soc. 2012;60(10):1979–80.CrossRefPubMed

Schofield PW, Finnie S, Yong YM. The role of olfactory challenge tests in incipient dementia and clinical trial design. Curr Neurol Neurosci Rep. 2014;14(9):479CrossRefPubMed

Claggett MS. Nutritional factors relevant to Alzheimer’s disease. J Am Diet Assoc 1989;89:392e6

Khater MS, Abouelezz NF. Nutritional status in older adults with mild cognitive impairment living in elderly homes in Cairo, Egypt. J Nutr Health Aging. 2011;15(2):104–8CrossRefPubMed

Roqué M, Salvà A, Vellas B. Malnutrition in community-dwelling adults with dementia (NutriAlz Trial). J Nutr Health Aging. 2013;17(4):295–9.CrossRefPubMed

Vellas B, Lauque S, Gillette-Guyonnet S et al. Impact of nutritional status on the evolution of Alzheimer’s disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging. 2005;9(2):75–80.PubMed

10.

Guerin O, Soto ME, Brocker P, Robert PH, Benoit M, Vellas B; REAL. FR Group. Nutritional status assessment during Alzheimer’s disease: results after one year (the REAL French Study Group). J Nutr Health Aging. 2005;9(2):81–4.PubMed

11.

Lam B, Hollingdrake E, Kennedy JL, Black SE, Masellis M. Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics. 2009;4(2):91–106.CrossRefPubMedPubMedCentral

12.

Baskys A, Cheng JX. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Exp Gerontol. 2012;47(11):887–91CrossRefPubMed

13.

Boeve BF, Josephs KA, Drubach DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol. 2008;89:533–48.CrossRefPubMed

14.

Droogsma E, van Asselt DZ, van Steijn JH, Schuur T, Huinink EJ. Effect of longterm treatment with galantamine on weight of patients with Alzheimer’s dementia. J Nutr Health Aging. 2013;17(5):461–5.CrossRefPubMed

15.

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 4th ed., text rev.; DSM-IV-TR, 2000

16.

Soysal P, Isik AT, Buyukaydin B, Kazancioglu RA. Comparison of end-stage renal disease and Alzheimer’s disease in the elderly through a comprehensive geriatric assessment. Int Urol Nephrol. 2014;46(8):1627–32.CrossRefPubMed

17.

Dina Zekrya, Bernardo Hermont Loures Valleb, Claudia Lardia et al. Geriatrics index of comorbidity was the most accurate predictor of death in geriatric hospital among six comorbidity scores. Journal of Clinical Epidemiology. 2010;63:1036–1044.CrossRef

18.

Babacan-Yildiz G, Isik AT, Ur E et al. COST: Cognitive State Test, a brief screening battery for Alzheimer disease in illiterate and literate patients. Int Psychogeriatr. 2013;25:403–12.CrossRefPubMed

19.

Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198CrossRefPubMed

20.

Alexopoulos GS, Abrams RC, Young RC, et al. «Cornell Scale for Depression in Dementia». Biological Psychiatry. 1988;23(3): 271–284.CrossRefPubMed

21.

Mahoney F. Barthel D. «Functional evaluation: the Barthel Index». Md Med J. 1965;14:61–65

22.

Lawton, M.P., Brody, E.M. Assessment of older people: Self-maintaining and instrumental activities of daily living. The Gerontologist. 1969;9(3):179–186.CrossRefPubMed

23.

Zarit S.H., Reever K.E., Bach-Peterson J. Relatives of the impaired elderly: correlated of feelings of burden. Gerontologist. 1980;20, 649–655.CrossRefPubMed

24.

Vellas B, Guigoz Y, Garry PJ et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15(2):116–22.CrossRefPubMed

25.

Soysal P, Isik AT, Ugur A, Kazancioglu R, Ergun F, Babacan Yildiz G. Vitamin B12 and folic acid levels are not related to length of stay in elderly inpatients. Nutrition. 2013;29(5):757–9.CrossRefPubMed

26.

Saka B, Kaya O, Ozturk GB, Erten N, Karan MA. Malnutrition in the elderly and its relationship with other geriatric syndromes. Clin Nutr. 2010;29(6):745–8.CrossRefPubMed

27.

Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia Alzheimers Res Ther. 2013;8:5.

28.

Stewart JT, Gorelik AR. Involuntary weight loss associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2006;54(6):1013–4.CrossRefPubMed

29.

Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;27;54(12):2261–8.CrossRef

30.

Gillette-Guyonnet S, Cortes F, Cantet C, Vellas B; REAL.FR Group. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer’s disease: data from the French REAL.FR cohort. J Nutr Health Aging. 2005;9(2):69–73.PubMed

31.

Kaiser MJ, Bauer JM, Ramsch C et al. MNA-International Group Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging. 2009;13(9):782–8CrossRefPubMed

32.

Cortes F, Portet F, Touchon J, Vellas B. Six and 18-month changes in mild to moderate Alzheimer’s patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? J Nutr Health Aging. 2007;11(4):330–7PubMed

33.

Cortes F, Gillette-Guyonnet S, Nourhashemi F. Recent data on the natural history of Alzheimer’s disease: results from the REAL.FR Study. J Nutr Health Aging. 2005;9(2):86–93.PubMed

34.

de Toledo-Morrell L, Dickerson B, Sullivan MP et al. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer’s disease. Hippocampus 2000;10, 136–142. 33CrossRefPubMed

35.

Ober BA, Jagust WJ, Koss E et al. Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer’s disease. J Clin Exp Neuropsychol 1991;13, 752–772CrossRefPubMed

36.

Lyketsos CG, Lopez O, Jones B et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288, 1475–1483.CrossRefPubMed

37.

Dando R, Roper SD. Acetylcholine is released from taste cells, enhancing taste signalling. J Physiol. 2012;1;590(Pt 13):3009–17.CrossRef

38.

Jia YX, Li JQ, Matsui T et al. Neurochemical regulation of swallowing reflex in guinea pigs. Geriatr Gerontol Int. 2001;1:56–61.CrossRef

39.

Lee JH, Sevigny J. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(1):58–62.CrossRefPubMed

40.

Nakamura Y, Imai Y, Shigeta M et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):163–79..CrossRefPubMedPubMedCentral

41.

Wilson MM, Thomas DR, Rubenstein LZ et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr. 2005;82(5):1074–81PubMed

42.

Tully MW, Lambros Matrakas K, Musallam K. The eating behavior scale: a simple method of assessing functional ability in patients with Alzheimer’s disease. J Nutr Health Aging. 1998;2(2):119–21PubMed

Titel: Effects of acetylcholinesterase inhibitors on nutritional status in elderly patients with dementia: A 6-month follow-up study
verfasst von: P. Soysal
Ahmet Turan Isik
Publikationsdatum: 10.10.2015
Verlag: Springer Paris
Erschienen in: The journal of nutrition, health & aging / Ausgabe 4/2016
Print ISSN: 1279-7707
Elektronische ISSN: 1760-4788
DOI: https://doi.org/10.1007/s12603-015-0603-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Design, setting and participants

Measurements

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Keto-supplemented low protein diet: A valid therapeutic approach for patients with steroid-resistant proteinuria during early-stage chronic kidney disease

Defining rehabilitation success in older adults with dementia – results from an inpatient geriatric rehabilitation unit

The prognostic value of high-sensitivity C-reactive protein and prealbumin for short-term mortality in acutely hospitalized multimorbid elderly patients: A prospective cohort study

Evaluation of a continuing educational intervention for primary health care professionals about nutritional care of patients at home

Age-related changes in energy intake and weight in community-dwelling middle-aged and elderly Japanese